Ronaxan 100 mg for dogs 1 tablet
Treatment of respiratory tract infections including rhinitis, tonsillitis and bronchopneumonia in dogs due to organisms sensitive to doxycycline and treatment of arthropod-borne Ehrlichia canis, infection
RONAXAN 100mg Tablet
2. RONAXAN QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
Active substance :
Doxycycline 100 mg (as doxycycline hyclate)
For full list of excipients, see section 6.1.
3. RONAXAN PHARMACEUTICAL FORM
Round, biconvex, light yellow to yellow scored tablet. The tablets can be divided into equal parts.
4. RONAXAN CLINICAL PARTICULARS
4.1 Target species
4.2 Indications for use specifying the target species
Treatment of respiratory tract infections including rhinitis, tonsillitis and bronchopneumonia in dogs due to organisms sensitive to doxycycline including: Pasteurella spp., Bordetella bronchiseptica, Staphylococcus aureus and other Staphylococcus spp, and Streptococcus spp.
Treatment of arthropod-borne Ehrlichia canis, infection.
Do not use in pregnant animals.
Do not use in known cases of hypersensitivity to the active ingredient.
Vomiting, oesophagitis and oesophageal ulcerations have been reported as side effects following doxycycline therapy, and Ronaxan should not therefore be administered to patients with dysphagia or diseases accompanied by vomiting.
4.4 Special warnings for each target species
4.5 Special precautions for use
Special precautions for use in animals
Do not exceed the recommended dosage.
Tablets should be administered at feeding time.
ii) Special precautions to be taken by the person administering the medicinal product to the animals
Wash hands thoroughly after use. Handle the tablets with care if you know you are hypersensitive (allergic) to tetracycline. In the case of accidental ingestion, seek medical advice.
4.6 Adverse reactions (frequency and seriousness)
Photodermatitis has occurred following tetracycline therapy after exposure to intense sunlight or ultraviolet light.
Use of tetracycline during the period of tooth development may lead to tooth discolouration. Doxycycline, because of its lower affinity for calcium, carries a lower risk than other tetracyclines.
Refer also to section 4.3.
4.7 Use during pregnancy, lactation or lay
Laboratory studies have not revealed any teratogenic, or embryotoxic effect of doxycycline in the rat and rabbit. However, as there is no information available in the target species, use is not recommended during pregnancy.
4.8 Interaction with other medicinal products and other forms of interaction
Cross resistance to other tetracyclines can occur.
Doxycycline should not be used concurrently with other antibiotics especially bactericidal drugs such as the ß-lactams.
The half life of doxycycline is reduced by concurrent administration of barbiturates or phenytoin.
Simultaneous administration of oral absorbents, iron preparations and antacids should be avoided as they reduce doxycycline availability.
4.9 Amounts to be administered and administration route
The tablets are for oral administration. The dosage is 10 mg doxycycline per kilogram bodyweight (one tablet per 10 kg bodyweight) administered daily for up to five days. In order to adjust the dosage, the tablets can be divided into two equal parts.
For treatment of infections caused by Ehlichia canis the dose is 10 mg/kg/day for 28 days. Complete eradication of the pathogen is not always achieved but extended treatment for 28 days leads to a resolution of the clinical signs and a reduction of the bacterial load. Longer duration of treatment, based on a benefit:risk assessment by the responsible veterinarian, may be required in severe and chronic ehrlichiosis. All treated patients should be regularly monitored even after clinical cure.
Tablets should be administered at feeding time.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
Raised levels of SGPT, GGT, SAP and total bilirubin were noted in dogs which received three or five times the recommended dose. Some vomiting can occur in dogs with five times the recommended dosage.
4.11 Withdrawal periods
5. RONAXAN PHARMACOLOGICAL PROPERTIES
Summary presentation of the active ingredient
Doxycycline is a second generation, broad spectrum cycline belonging to the tetracycline family.
ATC Vet Code:
5.1 Pharmacodynamic properties
It is active against a large number of Gram positive and Gram negative pathogens including strains resistant to first generation tetracyclines. It is essentially bacteriostatic; it inhibits the bacterial protein synthesis by blocking binding of transfer RNA to the messenger RNA-ribosome complex.
5.2 Pharmacokinetic properties
After oral administration in dogs at the recommended dose of 10 mg/kg, doxycycline is rapidly absorbed reaching the maximal plasma concentration of4.5 µg/ml (Cmax) in about 3 hours (Tmax). The oral bioavailability of doxycycline after repeated administration is approximately 45%, and is not affected by the presence of food.
In spite of a high protein binding rate, the volume of distribution of doxycycline is high demonstrating that doxycycline is broadly distributed in organs and tissues.
Doxycycline is mainly excreted as unchanged drug and eliminated in faeces and urine. Mean elimination half-life is 7.8 hours.
6. RONAXAN PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Magnesium Stearate Microcrystalline Cellulose
6.2 Major incompatibilities
6.3 Shelf life, when necessary after reconstitution of the medicinal product or when the immediate packaging is opened for the first time
6.4 Special precautions for storage
Do not store above 25°C. Store in a dry place. Protect from light.
6.5 Nature and composition of immediate packaging
Thermoformed blister packs that consist of an opaque white sheet of a poly vinyl chloride acetyl chloride complex (sheet 250 microns in thickness) and aluminium foil 20 microns in thickness. Each blister contains 10 tablets.
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate.
Any unused product or waste material should be disposed of in accordance with national requirements.
7. MARKETING AUTHORISATION HOLDER
Merial Animal Health Ltd PO Box 327 Sandringham House Harlow Business Park Harlow Essex CM19 5TG